Nairobi — South Africa has emerged as a crucial country for clinical trials in AstraZeneca's global operations, playing a pivotal role in advancing medical research and delivering innovative ...

AstraZeneca’s presence in South Africa has become a driving force in global health research, contributing significantly to respiratory, cardiovascular, and oncology therapeutic areas. The ...

Other pharmaceutical players such as Roche, Amgen, Pfizer, AstraZeneca and Boehringer also have obesity ... Only diabetes ...

SINGAPORE – Pharmaceutical giant AstraZeneca is set to create over 800 skilled jobs here to staff a new manufacturing facility in Tuas South. The jobs range from those in engineering and ...

AstraZeneca received these accolades across several countries, including Jordan, Lebanon, Iraq, Tunisia, Algeria, and Morocco, reflecting its dedication to fostering a positive and supportive culture ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Pharmaceutical giant AstraZeneca, whose China president is under investigation, was previously investigated for medical insurance fraud cases involving cancer medication sales, according to new ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

AstraZeneca has paused its planned £450 million investment in the UK for vaccine R&D as it continues discussions with the ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Discover how AI is ...

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.